L-Serine- A possible natural solution to ALZHEIMERS
Summary of fortune article with respect to Alzheimer’s disease and L-serine as a possible treatment. You can read the full article here.
An article was published in Fortune magazine in February of 2019 concerning the possible prevention of Tangle diseases by the daily dosing of L-serine- a naturally occurring Amino acid used by the body to prevent the misfolding of proteins – which protects neurons in the brain.
The research was done by DR. Paul Cox, PHD and the Brain Chemistry Labs in Jackson Hole, Wyoming. They have published research on their findings and have concentrated their efforts on L-serine which they believe could significantly delay the onset of Alzheimer’s and the progress of its symptoms. The FDA has previously approved the use of L-serine as a safe dietary supplement, and doctors sometime proscribe it for chronic fatigue syndrome. The Cox team believes L-serine may play a neuroprotective role.
For Cox, the most powerful illustration of L-serine potential is a 2016 study he and the University of Miami’s Mash oversaw on St. Kitts in the British Virgin Islands. A team at an animal research lab there fed bananas loaded with BMAA -identified to cause tangles, L-serine, or a combination of both to vervet monkeys who have a gene that is thought to increase the risk of Alzheimer’s in humans.( The control Group got bananas with rice flour). Monkeys given BMAA showed both plaques and tangles common to Alzheimer’s patients. But those given an accompanying dose of L-serine had 80% to 90% fewer tangles in their brain tissue, the study found. The results astounded Mash and Cox, so they repeated the effort with another 140 vervets and got comparable results. Their findings were published in the PROCEEDINGS of the ROYAL SOCIETY.
Early in 2017, Cox published the results of a six-month clinical trial of L-serine given at varying doses to ALS patients. The phase I trial, conducted by independent labs in San Francisco and Phoenix, showed once again that L-serine is safe for humans. One piece of data stood out which was published in a respected ALS journal. The four patients who received the highest doses of L-serine (30 grams a day) saw the progress of their symptoms, as measured on a widely used scale known as ALSFRS-R, slow by 85%. The number of patients, in this case, was too small for the finding to reach statistical significance, but if further clinical trials replicate anything close to that percentage, L-serine would slow the progress of symptoms far more than any existing drug, potentially buying patients years of life. (the average ALS patient dies 2.5 years after diagnosis).
Cox and the brain chemistry labs are conducting Phase II trials currently at Dartmouth medical school and in North Carolina. They are expecting results sometime this year that will support the pervious trials.
In the absence of a cure, the pool of Alzheimer’s patients will soar: while 47 million people worldwide live with Alzheimer’s today, 141 million may have the disease in 2050, according to the Alzheimer’s association. In the US alone, the financial cost of caring for today's 5.7 million patients is a staggering annual $277 billion. By mid-century, Americans may spend $1.1 trillion annually on Alzheimer’s, a crippling blow to a reeling health care system.